BioCentury | Feb 18, 2021
Finance
With $300M fund, Adjuvant picks its spots among start-ups addressing global public health needs
...Themis Bioscience GmbH, which Merck & Co. Inc. (NYSE:MRK) acquired last year.Other portfolio companies include MinervaX ApS...